ADAP News and Press, Adaptimmune Therapeutics plc From 07/08/21

Baker Brothers’ 13F portfolio value decreased from $26.54B to $23.07B this quarter. The large stake in Alexion Pharmaceuticals was decreased during the quarter. The top three positions are Seagen, BeiGene, and Incyte Corporation and they add up to almost ~57% of the portfol...

Shares of Adaptimmune Therapeutics plc (NASDAQ:ADAP) traded at a new 52-week low today of $3.68. Approximately 263,000 shares have changed hands today, as compared to an average 30-day volume of 1.1 million shares. There is potential upside of 5.5% for shares of Adaptimmune Therapeutics ...

Dogecoin (CRYPTO: DOGE) , in many ways, is at the epicenter of the cryptocurrency craze. Its price appreciated by a staggering 12,000% during just the first five months of 2021. The probability that this star of the cryptocurrency world will keep churning higher, however, appears to...

I covered Adaptimmune in December. This article covers all that has changed since then. A BLA filing next year could be a major catalyst. For further details see: Adaptimmune Therapeutics: Still The TCR Leader, And With Major Upcoming Catalysts

ASCO is a very important cancer clinical research meeting. We identified 70 smid-cap cancer companies presenting updated clinical data at ASCO21. 13 companies' value increased by over 10% with ASCO21 info release thus far. PDSB is an early ASCO21 mover, with its HPV vaccine ca...

Seeing a bigger upside from overweight-rated stocks in its coverage, Barclays has initiated Adaptimmune Therapeutics ([[ADAP]] -2.0%) with an underweight recommendation.The price target of $4.00 per share indicates a downside of ~20.8% to the previous close. After two consecutive days of gain...

Adaptimmune Therapeutics (NASDAQ: ADAP) , a biotech company active in the hot immunotherapy segment, was a high-temperature stock on Thursday. Following the release of detailed phase 2 clinical trial results for a promising cancer treatment, the company's shares rose by nearly 4.5% ...

Adaptimmune Therapeutics shares rise ([[ADAP]] +4.9%) as the company talked up initial data from its mid-stage afamitresgene autoleucel cancer trial ahead of its presentation at the upcoming American Society of Clinical Oncology ((ASCO)) congress.At the time of data cut-off, 37 patients had r...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Welcome back once again, investors, and let’s get ready for a busy day of trading! We’re kicking off the day with a look at the biggest pre-market stock movers for Thursday below. Source: oneinchpunch/Shut...

- Data will support BLA filing for afamitresgene autoleucel next year - - Responses observed across a broad range of antigen expression - - Initial safety and durability are encouraging - PHILADELPHIA and OXFORDSHIRE, United Kingdom, May 19, 2021 (GLOBE NEWSWIRE) -- Adaptimmun...